Radiographic structural damage in axial spondyloarthritis: is there a preferred way to quantify progression over time? Comparison of blinded versus unblinded mSASSS scoring. (2025)
https://pubmed.ncbi.nlm.nih.gov/40379523/

Association between resolution of MRI-detected inflammation and improved clinical outcomes in axial spondyloarthritis under long-term anti-TNF therapy. (2025)
https://pubmed.ncbi.nlm.nih.gov/39762123/

Achieving inactive disease state in men and women with axial spondyloarthritis: results from a multi-country prospective observational study. (2025)
https://pubmed.ncbi.nlm.nih.gov/40833778/

Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trial. (2024)
https://pubmed.ncbi.nlm.nih.gov/38228361/

HLA-B27 and the role of specific T cell receptors in the pathogenesis of spondyloarthritis. (2024)
https://pubmed.ncbi.nlm.nih.gov/38575323/

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension (2022)
https://pubmed.ncbi.nlm.nih.gov/34196498/

Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial (2020)
https://pubmed.ncbi.nlm.nih.gov/31813637/

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (2020)
https://pubmed.ncbi.nlm.nih.gov/31685553/

Axial spondyloarthritis (2017)
https://pubmed.ncbi.nlm.nih.gov/28110981/